State Street Corp Galectin Therapeutics Inc Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, State Street Corp holds 251,014 shares of GALT stock, worth $667,697. This represents 0.0% of its overall portfolio holdings.

Number of Shares

251,014

Previous 229,615 9.32%

Holding current value

$667,697

Previous $518,000 33.2%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.04 - $2.86 $43,653 - $61,201	21,399 Added 9.32%	251,014 $690,000
Q2 2024 Aug 14, 2024	BUY	$2.13 - $4.2 $145,212 - $286,335	68,175 Added 42.23%	229,615 $518,000
Q2 2023 Aug 14, 2023	SELL	$1.32 - $2.08 $16,236 - $25,584	-12,300 Reduced 7.08%	161,440 $232,000
Q1 2022 May 16, 2022	BUY	$1.61 - $2.31 $24,119 - $34,606	14,981 Added 9.44%	173,740 $280,000
Q2 2021 Aug 16, 2021	SELL	$2.07 - $5.1 $944,406 - $2.33 Million	-456,235 Reduced 74.19%	158,759 $508,000
Q1 2021 May 17, 2021	SELL	$1.96 - $2.57 $110,544 - $144,948	-56,400 Reduced 8.4%	614,994 $1.34 Million
Q4 2020 Feb 16, 2021	SELL	$2.24 - $2.87 $59,850 - $76,683	-26,719 Reduced 3.83%	671,394 $1.5 Million
Q3 2020 Nov 10, 2020	BUY	$2.53 - $3.64 $25,375 - $36,509	10,030 Added 1.46%	698,113 $1.86 Million
Q2 2020 Aug 14, 2020	BUY	$1.66 - $3.15 $40,338 - $76,545	24,300 Added 3.66%	688,083 $2.11 Million
Q1 2020 May 11, 2020	BUY	$1.51 - $3.0 $1 Million - $1.99 Million	663,783 New	663,783 $1.3 Million

Others Institutions Holding GALT

# of Institutions

Shares Held

9.44M

Call Options Held

1.16M

Put Options Held

1.98M

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $158M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Galectin Therapeutics Inc Transaction History